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Abstract
Myocardial fibrosis, a major pathophysiologic substrate of heart failure with preserved ejection fraction (HFPEF), is
modulated by multiple pathways including the renin-angiotensin system. Direct renin inhibition is a promising anti-fibrotic
therapy since it attenuates the pro-fibrotic effects of renin in addition to that of other effectors of the renin-angiotensin
cascade. Here we show that the oral renin inhibitor aliskiren has direct effects on collagen metabolism in cardiac fibroblasts
and prevented myocardial collagen deposition in a non-hypertrophic mouse model of myocardial fibrosis. Adult mice were
fed hyperhomocysteinemia-inducing diet to induce myocardial fibrosis and treated concomitantly with either vehicle or
aliskiren for 12 weeks. Blood pressure and plasma angiotensin II levels were normal in control and hyperhomocysteinemic
mice and reduced to levels lower than observed in the control group in the groups treated with aliskiren. Homocysteine-
induced myocardial matrix gene expression and fibrosis were also prevented by aliskiren. In vitro studies using adult rat
cardiac fibroblasts also showed that aliskiren attenuated the pro-fibrotic pattern of matrix gene and protein expression
induced by D,L, homocysteine. Both in vivo and in vitro studies demonstrated that the Akt pathway was activated by
homocysteine, and that treatment with aliskiren attenuated Akt activation. In conclusion, aliskiren as mono-therapy has
potent and direct effects on myocardial matrix turnover and beneficial effects on diastolic function.
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Introduction
Heart failure with preserved ejection fraction (HFPEF) is
increasing in prevalence and is associated with significant
morbidity and mortality [1]. Myocardial fibrosis resulting in
increased myocardial stiffness and diastolic dysfunction is a major
pathophysiological component of HFPEF [2]. Activation of the
renin-angiotensin-aldosterone system (RAAS) has been shown to
promote myocardial fibrosis and diastolic dysfunction [3].
However, recent clinical trials of the use of angiotensin converting
enzyme inhibitors (ACEI) and angiotensin II type 1 receptor
blockers (ARBs) have not shown a benefit in HFPEF patients [4–
6]. One of the potential reasons for the lack of efficacy of ACEI
and ARB in clinical trials is that the anti-fibrotic effects of these
agents alone or in combination require supra-therapeutic dose
ranges [7]. Aliskiren, as a direct renin inhibitor, functions through
inhibition of angiotensin II effects as well as angiotensin II-
independent effects mediated via the (pro)renin receptor as shown
in recent studies [8,9]. To examine whether aliskiren has potent
and direct anti-fibrotic effects, we studied the effects of aliskiren in
a unique model of hyperhomocysteinemia-induced myocardial
fibrosis and diastolic dysfunction, which is not associated with
hypertension or left ventricular hypertrophy. We observed that
aliskiren as mono-therapy has potent and direct effects on
myocardial matrix turnover and thereby on diastolic function,
suggesting that direct renin inhibition might be an effective
therapy in HFPEF.
Materials and Methods
Animal model
The study was conducted in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
procedures in this study were approved by the Institutional Animal
Care and Use Committee of Boston University School of Medicine
(Protocol # AN-15057) and Harvard Medical School (Protocol #
04783). Male C57BL6 mice (8–10 weeks old) were purchased
from Charles River Laboratories (Boston, MA, USA) and were
maintained in our institutional Division of Laboratory Animal
Medicine on a 12:12 light-to-dark cycle with free access to chow
and water. Osmotic mini-pumps for delivery of aliskiren (drug
provided by Novartis Pharmaceuticals) were implanted subcuta-
neously in the dorsal chest under anesthesia. Either vehicle, or
aliskiren in the doses of 0.5 mg/kg/day, 5 mg/kg/day, or 50 mg/
kg/day, was delivered via osmotic mini-pump. Since aliskiren is
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designed to specifically inhibit human renin, higher doses are
required to inhibit murine renin, and 50 mg/kg/day is a widely
accepted dose to provide adequate inhibition of murine rennin
[10]. Immediately after implantation of mini-pumps, animals were
started on control amino-acid defined diet or hyperhomocystei-
nemia (Hhe)-inducing diets used in our prior studies [11]. Diets
were continued for a total of 12 weeks. Since osmotic mini-pumps
can deliver drug only for 6 weeks, repeat surgery and implantation
of new osmotic mini-pumps to deliver drug was done at 6 weeks.
Blood pressure was measured at 12 weeks of treatment in awake
animals using a noninvasive computerized tail-cuff system (BP-
2000 Visitech Systems, Apex, NC). Euthanasia was performed by
inducing general anesthesia using ketamine and xylazine after
12 weeks of treatment and blood was collected for measurement of
angiotensin II and hearts were collected for functional, histologic
and biochemical analysis.
Histological analysis of myocardial remodeling
Coronal sections of ventricular myocardium were fixed in 10%
neutral buffered formalin, and serial sections (5 mm) were stained
with hematoxylin and eosin for estimating myocyte size, and with
Picrosirius red for estimating fibrillar collagen. Perivascular
collagen, coronary arteriolar wall thickening, interstitial collagen
volume fraction, and myocyte size were measured as described
previously [12].
Measurement of cardiac function
Cardiac function was measured ex vivo utilizing isolated perfused
Langendorff heart preparations [12]. Age matched mice were used
as a control group. Briefly, mice were heparinized (100 U,
intraperitoneally) and anesthetized by sodium pentobarbital
(150 mg/kg, intraperitoneally). The heart was excised and
perfused at a constant pressure of 80 mm Hg at 37uC. The
perfusate was equilibrated with 95% O2 and 5% CO2 (pH 7.4)
and contained the following (in mmol/L): NaCl (118), NaHCO3
(25), KCl (5.3), CaCl2 (1.8), MgSO4 (1.2), glucose (10) and
pyruvate (0.5). Hearts were paced at 7.5 Hz throughout the
protocol. A water-filled balloon was inserted into the left ventricle
(LV) to record ventricular pressure. After 20 min stabilization, a
LV pressure–volume (P–V) relationship was obtained by stepwise
increases of the balloon volumes, until the maximum LV
developed pressure was reached for each heart. To correct for
variation in heart size, LV volume was normalized to heart weight.
Real-time PCR analysis
Total RNA was extracted from frozen mouse heart sections
using RNeasy Fibrous Tissue Mini-columns (catalog # 74704,
Qiagen Inc. Germantown, MD). High Capacity cDNA Reverse
Transcription Kit (catalog # 4374966, Applied Biosystems, Foster
City, CA) was utilized to make cDNA from 1 mg of RNA. Real-
time PCR was performed using the TaqMan universal PCR
mastermix (catalog # 4304437, Applied Biosystems, Foster City,
Figure 1. Effect of aliskiren on blood pressure and plasma angiotensin II levels. Data was obtained after 12 weeks of treatment with Hhe-
inducing diets and aliskiren. A. Heart weight to body weight ratios; B. Angiotensin II levels; C. Systolic blood pressure; and D. Diastolic blood pressure.
HW – heart weight; BW – body weight; Hhe – Hhe-inducing diet; AL 0.5– aliskiren 0.5 mg/kg/day; AL 5– aliskiren 5 mg/kg/day; AL 50– aliskiren
50 mg/kg/day; * – p,0.05; ** – p,0.01; and ***– p,0.001.
doi:10.1371/journal.pone.0081612.g001
Renin and Myocardial Fibrosis
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CA) and the TaqMan inventoried FAM labeled Gene Expression
assays for alpha 1 chain of type I collagen (COL1A1; catalog #
Mm00801666_g1 for mouse, catalog # Rn01463848_m1 for rat),
alpha 2 chain of type I collagen (COL1A2; catalog #
Mm01165187_m1 for mouse, catalog # Rn00670305_m1 for
rat), and alpha 1 chain of type III collagen (COL3A1; catalog #
Mm01254476_m1). Data were normalized by multiplexing with
the Taqman inventory VIC labeled gene expression assay for
GAPDH (catalog # 4352339e for mouse, catalog # 4352338e for
rat) endogenous control assay and expression was compared
relative to control treated samples using the formula, 22DDCT, on
the Step One Applied Real-Time PCR System Instrument
(Applied Biosystems). The PCR cycling conditions were 50uC
for 10 minutes, 95uC for 5 minutes, followed by 40 cycles of 95uC
for 15 seconds and 60uC for 1 minute. Data were analyzed using
the comparative cycle threshold (Ct) method.
Measurement of plasma angiotensin II level
Plasma angiotensin II level was measured in the Harvard
Catalyst Central Laboratory utilizing a double-antibody radioim-
munoassay using modification of the method described by
Emmanuel et al [13]. Briefly reversed phase-extraction plasma
samples and standards were incubated for 16 hours with the anti-
angiotensin II antibody; 125I-angiotensin II was then added to
compete with angiotensin II present in samples and standards for
the same binding sites on the anti-angiotensin II antibody. After
further incubation for 6 hours, the solid phase second antibody
was added to the mixture, and the antibody-bound fraction was
precipitated and counted.
Cell Culture
Adult rat cardiac fibroblasts were isolated and cultured as
described previously in publications from our laboratories [14].
Cardiac fibroblasts (passage 1) which were 80–90% confluent were
serum-deprived for 24 hours before initiation of treatments. Cells
were exposed to the pro-fibrotic stimulus D, L, homocysteine in
the concentrations of 0 or 400 mmol/L with or without pre-
exposure to aliskiren 0, 0.1, 1, or 10 mmol/L. Both cells and
conditioned media were collected at the end for measurement of
collagen turnover. To test the Akt signaling pathway, Wortmannin
Figure 2. Aliskiren prevents reactive myocardial fibrosis induced by hyperhomocysteinemia. Upper panel shows representative sections
from various groups demonstrating that interstitial fibrosis (panels A, B, C and G) and perivascular fibrosis (Panels D, E, F and H) are decreased by low
and high dose aliskiren. Coronary arteriolar wall thickness did not vary between groups (I). Hhe – Hhe-inducing diet; AL 0.5– aliskiren 0.5 mg/kg/day;
AL 5– aliskiren 5 mg/kg/day; AL 50– aliskiren 50 mg/kg/day; *p,0.05; **p,0.01; and ***p,0.001.
doi:10.1371/journal.pone.0081612.g002
Renin and Myocardial Fibrosis
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(1 mmol/L) (PI3K inhibitor, Cell Signaling Technology, Beverly,
MA) and Akt Inhibitor VIII (1 mmol/L; Millipore, Billerica, MA)
were utilized. Losartan (0.1 mmol/L) and Captopril (0.3 mmol/L)
(Sigma-Aldrich Corp., St. Louis, MO) were used to block
angiotensin II function.
Western blot Analysis
Western blot analysis was conducted as described previously
(15). Primary antibodies utilized for this study were: Collagen I
(Millipore Corporation, Temecula, CA); phospho-Akt and Akt,
(Cell Signaling, Beverly, MA); and GAPDH (R and D Systems,
Minneapolis, MN).
Statistical Analysis
Data were evaluated by ANOVA with a Student-Newman-
Keuls post-hoc test or by t-test as appropriate using GraphPad Prism
(Graph Pad Software, La Jolla, CA). The criterion for significance
was a p value ,0.05. Data are reported as means 6 SEM.
Results
Effects of aliskiren on cardiac hypertrophy, blood
pressure and RAS.
As shown in Figure 1, the blood pressure values obtained in the
Hhe group treated with vehicle were not elevated compared to
those observed in normal mice [15]. Systolic and diastolic blood
pressures were decreased significantly below control values in the
groups given the aliskiren doses of 5 mg/kg/day and 50 mg/kg/
day compared to vehicle or aliskiren 0.5 mg/kg/day. The blood
pressure values in Hhe group and control group treated with
aliskiren 50 mg/kg/day were similar. Heart weight to body weight
ratios were similar between groups, suggesting that there was no
ventricular hypertrophy in any group. Cardiomyocyte size
estimated as cross-sectional diameter was similar between groups
(Control: 1660.4 mm; Hhe: 16.460.8 mm; Hhe + aliskiren
0.5 mg/kg/day: 16.760.8 mm; Hhe + aliskiren 5 mg/kg/day:
16.160.8 mm; and Hhe + aliskiren 50 mg/kg/day: 16.360.6 mm).
Plasma angiotensin II levels were decreased significantly only by
aliskiren 50 mg/kg/day (Figure 1).
Aliskiren prevents Hhe-induced reactive myocardial
fibrosis.
As shown in Figure 2, Hhe-induced perivascular and interstitial
fibrosis were attenuated by all three doses of aliskiren, including
the lowest dose of 0.5 mg/kg/day. Coronary arteriolar wall
thickness did not vary between groups (Figure 2). Figure 3
demonstrates the effects of aliskiren on expression of collagen type
I, the most commonly expressed collagen in the myocardium. The
expression of the genes for the alpha 1 chain (COL1A1) and alpha
2 chain (COL1A2) of type I collagen were decreased significantly
by aliskiren 50 mg/kg/day compared to vehicle. The amount of
collagen type I protein in the myocardium was significantly
Figure 3. Effects of aliskiren on myocardial matrix gene expression. Real time PCR was performed with ventricular tissue obtained from mice
after 12 weeks of treatment with control or Hhe-inducing diet and different doses of aliskiren. Figure 3A demonstrates changes in expression of
COL1A1(alpha 1 chain of type I collagen) and 3B shows changes in COL1A2(alpha2 chain of type I collagen) genes. Lower right panels (3C and 3D)
demonstrate the results of western blotting for collagen type I in various groups. Hhe – Hhe-inducing diet; AL 0.5– aliskiren 0.5 mg/kg/day; AL 5–
aliskiren 5 mg/kg/day; and AL 50– aliskiren 50 mg/kg/day. * p,0.05; and *** p,0.001.
doi:10.1371/journal.pone.0081612.g003
Renin and Myocardial Fibrosis
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decreased by all three doses of aliskiren compared to treatment
with vehicle. Hence aliskiren, even in doses that did not lower
angiotensin II levels or blood pressure, prevented Hhe-induced
myocardial fibrosis.
Aliskiren prevents diastolic dysfunction induced by
hyperhomocysteinemia.
Figure 4 demonstrates the effects of aliskiren on cardiac systolic
and diastolic function. Hhe worsened diastolic function as
evidenced by an upward displacement of the diastolic pressure-
volume relationship compared to control group, similar to our
published studies in rats (ANOVA; p,0.05) [11]. Treatment with
aliskiren in the dose of 50 mg/kg/day prevented diastolic
dysfunction and normalized the pressure-volume relationship
(ANOVA; p,0.05). There was no effect of Hhe or aliskiren on
systolic function.
Effects of aliskiren on matrix expression in cultured
cardiac fibroblasts.
Figure 5 demonstrates the effects of aliskiren pretreatment on
matrix gene expression in cardiac fibroblasts in the presence or
absence of D, L, homocysteine. Homocysteine (400 mmol/L)
increased mRNA levels for COL1A2 and COL3A1, which codes
for the alpha 1 chain of collagen type III, the second most
common collagen type observed in the heart (Figure 5A, 5B).
Aliskiren reduced the expression of COL1A2 gene at low,
intermediate and high doses, while the expression of COL3A1
was inhibited at intermediate and high doses. Losartan
(0.1 mmol/L), an angiotensin II type I receptor blocker, and
captopril (0.3 mmol/L), an angiotensin converting enzyme inhib-
itor, did not attenuate homocysteine-induced increase in COL1A2
gene expression (Figure 5C). The lower panels demonstrate the
effect of homocysteine and aliskiren on collagen type I protein
expression (Figure 5D and 5E). Homocysteine increased the
expression of collagen type I protein in cardiac fibroblasts, while
aliskiren attenuated the effects of homocysteine.
Effects of Aliskiren on Signal Transduction in Cultured
Cardiac Fibroblasts.
As shown in Figure 6 (upper panel), phospho-Akt expression
was significantly increased in heart tissues obtained from the Hhe
group treated with vehicle compared to the control diet group, and
was decreased to control values in the Hhe groups treated with
aliskiren. The lower panel of Figure 6 demonstrates the effects of
D, L Homocysteine (400 mmol/L) with and without addition of
Aliskiren (1 mmol/L), wortmannin (1 mmol/L) and Akt Inhibitor
VIII (1 mmol/L) on cultured cardiac fibroblasts. The increase in
collagen type I protein expression induced by exposure to D, L,
homocysteine was significantly decreased by aliskiren, wortmannin
and Akt inhibitor. The combination of aliskiren with wortmannin
or Akt inhibitor did not significantly increase the effect of either
agent on homocysteine-induced collagen expression. The amount
of phospho-Akt was significantly increased by homocysteine.
Aliskiren, wortmannin, and the Akt Inhibitor VIII significantly
decreased this effect. As in the case of collagen type I protein
levels, the combination of aliskiren with the inhibitors of Akt
pathway did not result in an additive effect on Akt phosphory-
lation.
Discussion
Our results show that in a non-hypertensive, non-hypertrophic
model of myocardial fibrosis and diastolic dysfunction [11,16],
long-term treatment with aliskiren significantly reduced matrix
gene expression and improved diastolic function. Our in vitro
results demonstrate that aliskiren directly attenuates the pro-
fibrotic effects of homocysteine on cultured cardiac fibroblasts, and
that the Akt pathway is involved in the beneficial effects of
aliskiren. Cumulatively, our results suggest that direct renin
inhibition with aliskiren exerts potent anti-fibrotic effects in the
myocardium via both systemic effects on RAAS and direct effects
on cardiac fibroblast biology, and thereby demonstrates the
potential benefit of aliskiren in HFPEF.
Our results suggest that aliskiren can directly attenuate fibrotic
mechanisms in the myocardium and normalize diastolic function
in an established model of myocardial fibrosis. Although plasma
angiotensin II levels and blood pressure were in the normal range
in the Hhe group treated with vehicle, aliskiren dose dependently
decreased both systolic and diastolic blood pressure and plasma
angiotensin II levels on long-term treatment. A limitation of our in
vivo study is that we did not directly compare the effect of aliskiren
to an antihypertensive that acted independent of RAAS, or to
another RAAS inhibitor. Since the blood pressure and angiotensin
II levels in aliskiren groups were similar in both control and Hhe
treated animals exposed to the highest does of aliskiren, it is not
Figure 4. Effects of aliskiren on Hhe-induced diastolic dysfunc-
tion. (n = 5–7/group). A, the relation of balloon volume (normalized to
heart weight) to left ventricular developed pressure. There were no
differences between the groups. B shows the relation of balloon
volume to left ventricular end diastolic pressure. There was a significant
displacement of the pressure volume curve upwards in the Hhe group
compared to all other groups (ANOVA; p,0.05). Hhe – Hhe-inducing
diet; LVEDV – left ventricular end diastolic volume; and LVDevP – left
ventricular developed pressure.
doi:10.1371/journal.pone.0081612.g004
Renin and Myocardial Fibrosis
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clear whether these systemic effects may have played a role in the
anti-fibrotic effects of aliskiren. The observation that the heart
weight to body weight ratios and cardiomyocyte size were similar
in all groups suggests that the effects were independent of any
load-induced ventricular hypertrophy. In addition, the anti-
fibrotic effects of aliskiren were also observed at doses that did
not alter blood pressure or angiotensin II levels. Recent
investigations also suggest that the beneficial effects of aliskiren
may be independent of blood pressure lowering. For example, in a
mouse model of post-myocardial infarction heart failure, aliskiren
was shown to have better effects on ventricular remodeling
compared to a dose of hydralazine that produced comparable
blood pressure lowering [17]. A similar study using high doses of
aliskiren was shown to prevent the activation of extracellular signal
regulated kinase and p38 mitogen activated protein kinase in the
infarcted heart and to improve left ventricular function without
decreasing the blood pressure [10].
Our results suggest that the myocardial matrix is a major target
of aliskiren’s cardiovascular effects. Myocardial type I collagen
mRNA and protein levels induced by Hhe were reduced by
exposure to lower doses of aliskiren. Our in vitro results corroborate
our in vivo findings and suggest a direct anti-fibrotic effect of
aliskiren on cardiac fibroblasts. Homocysteine-induced increase in
the expression of collagen types I and III genes were suppressed by
aliskiren in lower doses. Similar effects were observed on collagen
type I protein levels secreted into the culture medium. Multiple
studies have shown similar effects of renin, prorenin and their
inhibition by inhibitors including aliskiren on matrix turnover in
stromal cells. For example, He and coworkers have shown that
(pro)renin receptor blockade resulted in anti-proliferative and anti-
fibrotic effects in cultured rat mesangial cells [18]. Similarly, in rat
Figure 5. Effects of aliskiren on homocysteine-induced matrix expression in cultured cardiac fibroblasts. Fibroblasts were cultured in
the presence or absence of D,L, homocysteine 200 mmol/L for 24 hours after pretreatment with varying concentrations of aliskiren (0.1–10 mmol/L).
Real time PCR was done to measure relative expression of COLIA2 (alpha 2 chain of type I collagen; A) and COL3A1 (alpha 1 chain of type III collagen;
B) genes. Figure 5C demonstrates the results of real time PCR to compare the effects of losartan and captopril with aliskiren on homocysteine induced
expression of COL1A2 gene. Western blotting was conducted to measure the expression of collagen type I protein (D and E) Glyceraldehyde 3
phosphate dehydrogenase (GAPDH) was used as internal control. Hcy-D,L, homocysteine; AL-aliskiren; Los – losartan; and Cap – captopril. *p,0.05.
doi:10.1371/journal.pone.0081612.g005
Renin and Myocardial Fibrosis
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and human mesangial cells, Huang and colleagues demonstrated a
(pro)renin receptor mediated, angiotensin II-independent effect of
renin in increasing transforming growth factor-b (TGF- b) and
matrix gene expression [19]. In our study, losartan and captopril
did not inhibit the effects of homocysteine on cardiac fibroblasts
suggesting that the anti-fibrotic effect of aliskiren is independent of
RAAS pathway. A recent study by Montes and colleagues in
human fibroblasts isolated from normal and fibrotic lungs and
demonstrated that renin, independent of angiotensin II, mediated
TGF-b and collagen secretion. Our studies show that aliskiren has
similar direct anti-fibrotic effects on cardiac fibroblasts.
Preclinical studies from our laboratories and those of others
have shown that Hhe promotes myocardial fibrosis and dysfunc-
tion [12,20,21]. Epidemiological and clinical studies have also
shown a link between Hhe and both diastolic and systolic heart
failure [22], as well as between plasma homocysteine and plasma
markers of matrix metabolism in subjects with normal and
remodeled hearts [23]. We utilized this clinically relevant model to
examine the effects of aliskiren on myocardial fibrosis. Multiple
mechanisms such as oxidant stress, methylation, and direct
incorporation of homocysteine into proteins or homocysteinyla-
tion, are proposed as pathogenic mechanisms of Hhe-induced
cardiovascular dysfunction [24]. Interestingly, several studies have
shown an interaction of the methionine-homocysteine cycle and
RAAS. For example, in vivo, hyperhomocysteinemia has been
demonstrated to enhance angiotensin II-induced vasoconstriction
[25], and conversely, angiotensin II has been shown to exacerbate
Hhe-induced changes in matrix accumulation and mechanics in
small arteries [26]. Similarly, Hhe-induced changes in cerebro-
vascular and aortic reactivity are attenuated by ACEI [27–29].
The exact mechanism of this interaction is not known; a study by
Suzuki and colleagues have shown that in cultured fibroblasts,
Figure 6. Role of Akt pathway in aliskiren’s effects on attenuating collagen expression. A and B demonstrate the results of Western
blotting for phospho- and total Akt in hearts of mice treated with various diets. C shows changes in the protein levels of collagen type I, phospho-
and total Akt in response to 24 hours of exposure to D,L. Homocysteine (200 mmol/L) with or without pre-treatment with aliskiren 10 mmol/L (AL),
wortmannin 1 mmol/L or Akt Inhibitor VIII 1 mmol/L. Hhe – Hhe-inducing diet; D,L, homocysteine (lower panel); AL 0.05– aliskiren 0.5 mg/kg/day; AL
5– aliskiren 5 mg/kg/day; AL 50– aliskiren 50 mg/kg/day; Wort – wortmannin; Akt in – Akt inhibitor VIII. *p,0.05; **p,0.01; and ***p,0.001.
doi:10.1371/journal.pone.0081612.g006
Renin and Myocardial Fibrosis
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homocysteine modulated the effects of angiotensin II on expres-
sion of the transcription factors GATA-4, nuclear factor of
activated T cells and serum response factor [30]. Hence the
myocardial effects of Hhe observed in our study may be dependent
on homocysteine-induced activation of RAAS. The current study
does not allow a clear separation of angiotensin II-mediated and
angiotensin-II independent effects of aliskiren in myocardial
fibrosis, since we did not examine the tissue RAAS in detail.
However, since the effects of aliskiren were observed in cultured
cardiac fibroblasts as well as with an in vivo dose which did not
reduce plasma angiotensin II levels or blood pressure, it is likely
that the effects of aliskiren were mediated by inhibition of
(pro)renin receptor mediated and angiotensin II- independent
effects of renin and prorenin. Multiple studies have demonstrated
effects of prorenin and renin independent of the RAAS. In the
initial reports by Nguyen on the (pro)renin receptor, it was
demonstrated that renin-induced DNA synthesis was independent
of enzymatic activity [31]. The (pro)renin receptor has been shown
to modulate pro-fibrotic response in cultured mesangial cells [18]
independent of angiotensin II [19]. Signal transduction via
(pro)renin receptor is a major mode of cellular action of renin
and prorenin independent of angiotensin II. In vivo studies on rats
transgenic for the human (pro)renin receptor demonstrated that
mitogen activated protein kinase activation and TGB-b expression
was not attenuated by an ACEI, suggesting angiotensin II-
independent MAPK activation modulated via the (pro)renin
receptor [32].
Multiple signal transduction pathways including Phosphoinosi-
tide-3 kinase (PI3K)/Akt pathway has been shown to be induced
by prorenin in cultured vascular smooth muscle cells [33].
Abekhoukh and colleagues demonstrated that in mice with
hyperhomocysteinemia due to a genetically induced deficiency of
the enzyme cystathionine beta synthase, a specific kinase termed
dual-specificity tyrosine phosphorylation regulated kinase 1A
modulated the PI3K/Akt pathway resulting in increased levels
of phospho-Akt [34]. In another study, acute hyperhomocysteine-
mia was found to increase Akt phosphorylation in the rat
hippocampus, while chronic hyperhomocysteinemia did not alter
Akt phosphorylation [35]. In vitro studies have also demonstrated
a direct effect of homocysteine on the PI3K/Akt pathway [36]. A
study by Zou and colleagues demonstrated that homocysteine
activated the Akt pathway and promoted proliferation of hepatic
stellate cells [37]. Another study by Doronzo and colleagues
demonstrated that in cultured vascular smooth muscle cells,
homocysteine activated the PI3K/Akt pathways via the N-methyl-
D-aspartate receptor, a glutamate-gated calcium ion channel; the
increased in Akt phosphorylation was found to promote increased
secretion of MMP-2. [38] Similarly, in murine macrophages,
homocysteine increased Akt phosphorylation, and inhibition of
Akt phosphorylation attenuated homocysteine induced MMP-9
expression [39], while in rat glomerular mesangial cells, homo-
cysteine increased phosphorylation of PI3-kinase [40]. In these
studies and others, homocysteine activated not only Akt, but also
other signaling pathway such as ERK and p38MAPK. Hence
hyperhomocysteinemia acts through the Akt signaling pathway as
shown by our results; but the exact mechanisms of activation and
cross-talk with other signaling pathways need further elucidation.
Furthermore, the effect may be different in different cell types.
Our study demonstrated that homocysteine activated the Akt
pathway and that aliskiren’s effects on preventing homocysteine
induced matrix accumulation may be mediated via inhibiting
activation of the Akt pathway. The effect of aliskiren on Akt
activation is not well understood. Westermann and colleagues, in
their study of aliskiren in a rodent model of myocardial infarction,
demonstrated that myocardial phospho-Akt levels were increased
after MI [10]. In this study, aliskiren decreased Akt phosphory-
lation and ameliorated cardiac remodeling, similar to the results
observed in our study. The exact mechanisms by which renin
inhibition would ameliorate signaling via Akt pathway have not
been elucidated. Since renin can promote intracellular signaling by
direct binding to the (pro)renin receptor independent of angio-
tensin receptor activation, it is possible that renin may have direct
effect on kinases that promote signaling via the PI3K/Akt
pathway.
Conclusions
In conclusion, our results suggest that aliskiren exerts potent and
direct anti-fibrotic effects in a clinically relevant model of
myocardial fibrosis and diastolic dysfunction. Since current modes
of RAAS antagonism may not provide a potent anti-fibrotic effect
[7] and since ACEI and ARBs have not been shown to be of
benefit in HFPEF, our results suggest that aliskiren as monother-
apy may be useful in treating HFPEF.
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